drugset / Trial / NCT02040311
Topiramate: Long-Term Maintenance of Weight Loss Induced by Low-Calorie Diet in Obese Subjects
Phase 4
Terminated
701 enrolled
University of Copenhagen
R W Johnson Pharmaceutical Research Institute · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine the efficacy and safety of topiramate (96 mg or 192 mg daily) as compared to placebo in maintaining weight loss in obese subjects who participated in an eight week intensive non-pharmacologic weight loss program. The primary efficacy endpoint will be the percent change in body weight from enrollment visit to week 60.
Timeline
- Start
- 2000-08
- Primary completion
- 2002-06
- Completion
- 2002-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Topiramate | Small molecule | 96 mg | — |
| Subject | Topiramate | Small molecule | 192 mg | — |